Our story - Tissue Regenix

Commercialising academic research in regenerative medicine.

Spun out of the University of Leeds in 2006, Tissue Regenix commercialise research undertaken by our higher education and research partners around the world. Tissue Regenix listed on the Alternative Investment Market (AIM) on the London Stock Exchange in 2010, before opening the first subsidiary office Tissue Regenix Woundcare, Inc. in San Antonio, Texas in 2012. In 2017 Tissue Regenix also completed the successful acquisition of CellRight Technologies, based in San Antonio, Texas.

US $81BN

Expected value of the Global Regenerative Medicine Market by 2023¹

1998

Research begins into dCELL® technology at the University of Leeds

2006

Spun out of the University of Leeds

2010

Listed on the London Stock Exchange

2010

The Group receives a CE mark for the dCELL^® Vascular Patch

2012

Tissue Regenix Wound Care, Inc established in San Antonio, TX

2014

Commercial launch of DermaPure^® in the US

2015

Mediacare ‘Q’ Code granted for outpatient reimbursement

2016

DermaPure^® breaks through $1m sales mark

2017

DermaPure^® available under the FSS and Premier and Vizient GPOs

2017

Acquisition of CellRight Technologies

2018

Launch of DentalFix^™

2018

Signed distribution agreement with Arthrex, Inc.

2018

Signed distribution agreement with ARMS Medical for DermaPure^®

2018

Transfer of DermaPure^® manufacturing inhouse

2018

HTA licence approval for Leeds facility

2018

Arthrex EU distribution announcement

2019

Further GPO coverage increasing total to ~95%

2019

Secured up to $20m funding facility from MidCap Financial

2020

Securing the additional funding in June 2020 allowed the Group to commence a capacity expansion programme at the facility in San Antonio in July 2020.

1 Business Wire, Feb 22 2019

You may also be interested in